Loading...
•
Sep 30, 2024
Avidity Biosciences Q3 2024 Earnings Report
Reported financial results for the third quarter and highlighted recent corporate progress.
Key Takeaways
Avidity Biosciences reported positive del-zota data, initiated the biomarker cohort for the del-brax FORTITUDE study, and is on track with enrollment in the global Phase 3 HARBOR study for del-desiran. The company's cash position is approximately $1.6 billion.
Reported positive del-zota data from Phase 1/2 EXPLORE44 trial for DMD44.
Initiated biomarker cohort for del-brax FORTITUDE study for FSHD.
Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track.
Cash position of approximately $1.6 billion.
Avidity Biosciences
Avidity Biosciences
Avidity Biosciences Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Avidity plans to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations.